ПОЛИ-D,L-ЛАКТИД-КО-ГЛИКОЛИД – ПЕРСПЕКТИВНЫЙ ПОЛИМЕР ДЛЯ РАЗРАБОТКИ НАНОСИСТЕМ ДОСТАВКИ ЛЕКАРСТВЕННЫХ СРЕДСТВ (ОБЗОР)

Abstract

Abstract. This article is a literature review that describes the prospects for the use of poly-D,L-lactide-co-glycolide (PLGA) in pharmacy as a material for the development of nano-delivery agents for therapeutic agents. The aim of the review is to summarize information about modern drug delivery systems based on PLGA. Results. Biodegradable polymers play an important role in the development of the modern pharmaceutical industry and allow solving the problems of targeted delivery and controlled release of medicinal substances. Due to their exceptional properties, microparticles based on these polymers can protect drug molecules from instant degradation in vivo, while providing a customizable release rate and profile, and maximize their pharmacological effects by reducing their side effects. PLGA is considered one of the most successfully synthesized biodegradable polymers. For the creation of polymer nanostructures, PLGA has attracted attention due to its key controllable properties. It is biocompatible and biodegradable to non-toxic endogenous compounds. PLGA microparticle production methods are well-defined and easy to replicate in laboratory and industrial environments. The use of PLGA as a basis for nanoparticles, followed by surface modification, makes it possible to achieve such positive changes as an increase in the bioavailability of substances, leveling of unwanted side effects, the possibility of targeted drug delivery to target organs, maintaining a constant plasma concentration, and reducing the number of injections. The potential of PLGA nanoparticles for targeted and controlled delivery of various micro- and macromolecules, including drugs, peptides, proteins, monoclonal antibodies, growth factors and DNA, etc., has been widely studied. The field of application of these nanoparticles includes a wide range of pathologies, which is especially important in therapy oncological, cardiovascular, cerebrovascular and other diseases. The development and implementation of PLGA-based delivery nanostructures, providing targeted, prolonged release of therapeutic agents, will allow solving urgent problems of pharmacy and medicine. Conclusions. Based on the analysis of the literature data carried out by the authors, the prospects for the use of PLGA for the development of nanosystems for drug delivery are shown.